色瑞替尼治疗间变性淋巴瘤激酶阳性非小细胞肺癌的研究概况(5)
[13] KATAYAMA R,FRIBOULET L,KOIKE S,et al. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib[J]. Clin Cancer Res,2014,20(22):5686-5696.[14] DONG X,FERNANDEZ-SALAS E,LI E,et al. Elucidation of resistance mechanisms to second-generation ALK inhibitors alectinib and ceritinib in non-small-cell lung cancer cells[J]. Neoplasia,2016 ......
您现在查看是摘要页,全文长 3487 字符。